These findings collectively demonstrate that both genetic and pharmacological inhibition of HDAC3 in BMSCs suppresses AML proliferation and synergizes with venetoclax to exert a stronger anti-AML effect. This evidence concerns the gene HDAC3 and acute myeloid leukemia.